tiprankstipranks

David Hollander Insider Profile

4 Followers
David Hollander, Chief R&D Officer at Aerie Pharma, holds 30.75K shares in Aerie Pharma (Ticker: AERI), holds ― shares in Kiora Pharmaceuticals (Ticker: KPRX), holds 104.94K shares in Revance Therapeutics (Ticker: RVNC).
tipranks
David Hollander

David Hollander
Aerie Pharma (AERI)
Chief R&D Officer

Not Ranked
David Hollander has not reported sufficient informative transactions and therefore cannot be ranked.
Time Frame
1 Year
Compare to
No Benchmark

Insider Holdings

$324K
100.00%
0.00%
A breakdown of David Hollander's holdings

Insider Roles

Revance Therapeutics
(RVNC)
CMO & Global Therapeutics Lead
Kiora Pharmaceuticals
(KPRX)
Director
Roles that David Hollander holds in companies

Most Profitable Insider Trade

Stock:
Revance Therapeutics
(RVNC)
Rating:Informative Sell
Date:Nov 19, 2024 - Today
Return:+17.80%
The most profitable trade made by David Hollander

David Hollander's Trading History

Company Name
Last Transaction Date
Insider Position
Last Transaction
Last Transaction Amount
Holding Value
AERI
Aerie Pharma
Feb 08, 2022
Uninformative Sell
6.54K
$468.92K
Kiora Pharmaceuticals
Director
Revance Therapeutics
Nov 19, 2024
CMO & Global Therapeutics Lead
Informative Sell
16.30K
$324.28K
List of latest transactions for each holding click on a transaction to see David Hollander's performance on stock

David Hollander insider profile FAQ

What is the percentage of profitable transactions made by David Hollander?
The percentage of profitable transactions made by David Hollander is ―.
    What is the average return per transaction made by David Hollander?
    The average return per transaction made by David Hollander is ―.
      What stocks does David Hollander hold?
      David Hollander holds: AERI, KPRX, RVNC stocks.
        What was David Hollander’s latest transaction?
        David Hollander latest transaction was an Uninformative Sell of $6.54K.
          What was David Hollander's most profitable transaction?
          David Hollander’s most profitable transaction was an Informative Sell of RVNC stock on November 19, 2024. The return on the trade was 17.80%.
            What is David Hollander's role in Aerie Pharma?
            David Hollander's role in Aerie Pharma is Chief R&D Officer.
              How can I follow the stock ratings of top corporate insiders?
              Head over to our Expert Center to see a list of the Top 100 corporate insiders and follow the corporate insiders of your choice. Visit their profiles for more details about their stock transactions and see how they perform on a stock-by-stock basis.